Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TREACE MEDICAL CONCEPTS, INC. (TMCI)

Treace Medical Q3 revenue falls 4% to $48.3 million; net loss narrows to $12.6 million

Mixed Impact 4 of 5 earnings

Treace Medical reported third-quarter 2026 revenue of $48.3 million, down 4% from $50.2 million a year earlier, while its net loss narrowed to $12.6 million from $16.3 million. The company raised its full-year 2026 Adjusted EBITDA outlook to a loss of $1.0 million to $2.0 million, from a prior loss estimate of $3.0 million to $5.0 million, and narrowed its revenue range to $206 million to $210 million.

Key points

  • Q3 2026 revenue was $48.3 million, down 4% from $50.2 million in Q3 2025; the company said bunion kit sales volume excluding stocking distributors grew mid-single digits.
  • Q3 2026 net loss was $12.6 million, or $(0.19) per share, versus $16.3 million, or $(0.26) per share, a year earlier.
  • Q3 2026 Adjusted EBITDA was $0.3 million, compared with a loss of $2.6 million in Q3 2025.
  • Full-year 2026 revenue guidance is $206 million to $210 million, versus the prior $204 million to $212 million; cash usage reduction of about 50% was reiterated.

The filing

CompanyTREACE MEDICAL CONCEPTS, INC. (TMCI)
Form8-K, current report
Filed with the SECNov 6, 2026, 7:05 AM ET
Accession number0001193125-26-450715

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.